Answers are grounded in this paper and cite their sources.
Background: HIV/AIDS and hepatitis B virus (HBV) are two serious global health threats that co-occur and are resistant to antiretroviral therapy (ART). Milions of people worldwide lost their lives to acquired immunodeficiency in 2019.Thus, this study was aimed to evaluate the survival status of patients co-infected with HIV and hepatitis B viruses who are on antiretroviral therapy (HART). Methods: A retrospective cohort study design was conducted. Individuals with HIV-HBV co-infected with HIV mono-infected in six health facilities in Mekelle City from January 2009 to February 2018. The total sample size was 466, of which 94 were HBV exposed and 372 were unexposed for HBV on ART clients. Kaplan-Meier survival and Cox proportional hazard models for survival analysis were used. Data was analyzed using STATA version 14. Result: Of the total patients, 300 (64.3%) were females and most age groups were 15-30 years old, 199 (43%). Over 1960 person years of observation time at risk, 23 (24%) HIV-HBV co-infected and 26 (7%) HIV mono-infected died. In the adjusted analysis, HIV-HBV co-infected group had a 2.53 times increased hazard of death (aHR: 2.52; 95% CI: 1.31-4.85) than HIV mono-infected. Conclusion: In this cohort study, mortality is higher in the HIV-HBV co-infected group. Hence, special attention shall be given to HIV-HBV co-infected groups, to significantly reduce mortality, and contribute to alleviating public health burden.
No takes yet. Share an insight, caveat, or question.
Bidre et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: